NCT05965115 The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
| NCT ID | NCT05965115 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2023-07 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2023-07 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Eligibility Criteria
Inclusion Criteria: 1. Male or female over the age of 18; 2. First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria; 3. Understand the purpose and procedure of this trial and voluntarily participate in this screening study; 4. Participants should be willing and able to follow the study follow-up plan and other protocol requirements. Exclusion Criteria: Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma
Contact & Investigator
Peng Liu, PhD, MD
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT05965115 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05965115 currently recruiting?
Yes, NCT05965115 is actively recruiting participants. Contact the research team at liu.peng@zs-hospital.sh.cn for enrollment information.
Where is the NCT05965115 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05965115 clinical trial?
NCT05965115 is sponsored by Shanghai Zhongshan Hospital. The principal investigator is Peng Liu, PhD, MD at Fudan University. The trial plans to enroll 10,000 participants.